View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 7, 2021updated 11 Jul 2022 9:51am

Sound Pharmaceuticals to launch NIH-funded Covid-19 oral therapeutic trial

Sound Pharmaceuticals is all set to launch two Phase II clinical trials of an oral capsule, SPI-1005, for treating patients with moderate or severe Covid-19. 

Sound Pharmaceuticals is all set to launch two Phase II clinical trials of an oral capsule, SPI-1005, for treating patients with moderate or severe Covid-19.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Developed for various neurotologic, neuropsychiatric, and respiratory indications, SPI-1005 is a capsule with a small molecule called ebselen.

The latest development comes after Sound Pharmaceuticals received a Cooperative Grant award worth $3.1m from the US National Institutes of Health (NIH) unit National Center for Advancing Translational Sciences (NCATS) for evaluating SPI-1005.

Sound Pharmaceuticals co-founder and CEO Dr Jonathan Kil said: “We are honoured to receive NIH funding for this novel therapeutic application of ebselen in Covid-19.

“To our knowledge, these are the first Phase II studies of an Mpro or PLpro inhibitor in moderate and severe Covid-19.”

The two randomised, double-blind, placebo-controlled trials will enrol 120 subjects with moderate or severe Covid-19. They will receive SPI-1005 or placebo for seven or 14 days.

Furthermore, the company will assess whether SPI-1005 can enhance the body’s inflammatory and cellular immune response to Covid-19.

In a separate development, Moleculin Biotech and IQVIA Biotech are set to initiate potential clinical trials of the former’s drug, WP1122, for treating Covid-19.

Moleculin Biotech chairman and CEO Walter Klemp said: “Over the last quarter, we completed our pre-clinical data, interviewed CRO’s and decided that IQVIA Biotech has the experience and reach to best serve our clinical needs for this project.

“In addition, considering that the active ingredient in WP1122 is 2-deoxy-D-glucose (2-DG) and that 2-DG has now shown efficacy in a Phase II clinical trial conducted by an unrelated drug developer outside of the US, we believe that a sufficient efficacy rationale for WP1122 already exists to begin clinical trials.”

Initially developed as a potential cancer drug, WP1122 was designed to boost the drug-like properties of 2-DG, specifically by enhancing circulation time and tissue and organ uptake and concentration.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology